221 related articles for article (PubMed ID: 24475676)
1. [Insulin glargine. The most studied basal insulin].
Walter M
MMW Fortschr Med; 2013 Nov; 155(19):70-1. PubMed ID: 24475676
[No Abstract] [Full Text] [Related]
2. [Early insulin treatment in type 2 diabetes--yes].
Schumm-Draeger PM
Dtsch Med Wochenschr; 2013 May; 138(18):956. PubMed ID: 23613375
[No Abstract] [Full Text] [Related]
3. [HbA1c is too high despite tablets. With single injections toward better blood glucose values].
MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347083
[No Abstract] [Full Text] [Related]
4. ["Very good metabolic control by early insulin administration"].
Schumm-Draeger PM
MMW Fortschr Med; 2012 Jun; 154(12):25. PubMed ID: 22880291
[No Abstract] [Full Text] [Related]
5. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
[TBL] [Abstract][Full Text] [Related]
6. [Oral treatment of type 2 diabetes mellitus].
Palitzsch KD
Dtsch Med Wochenschr; 2012 Sep; 137(38):1859-68, quiz 1869-72. PubMed ID: 22971973
[No Abstract] [Full Text] [Related]
7. Concentrated insulin glargine (Toujeo) for diabetes.
Med Lett Drugs Ther; 2015 May; 57(1468):69-70. PubMed ID: 25941955
[TBL] [Abstract][Full Text] [Related]
8. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
[TBL] [Abstract][Full Text] [Related]
9. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
10. Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes.
Shaefer CF; Reid TS; Dailey G; Mabrey ME; Vlajnic A; Stuhr A; Stewart J; Zhou R
Postgrad Med; 2014 Oct; 126(6):93-105. PubMed ID: 25414938
[TBL] [Abstract][Full Text] [Related]
11. [Researchers illuminate diabetes therapy].
Pflege Z; 2014 Feb; 67(2):126. PubMed ID: 24730335
[No Abstract] [Full Text] [Related]
12. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
[TBL] [Abstract][Full Text] [Related]
13. Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.
Joseph JJ; Donner TW
Vasc Health Risk Manag; 2015; 11():107-16. PubMed ID: 25657589
[TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
Rodbard HW; Cariou B; Zinman B; Handelsman Y; Philis-Tsimikas A; Skjøth TV; Rana A; Mathieu C;
Diabet Med; 2013 Nov; 30(11):1298-304. PubMed ID: 23952326
[TBL] [Abstract][Full Text] [Related]
15. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
[TBL] [Abstract][Full Text] [Related]
16. [Basal insulin and GLP-1 agonist potentiate each other (interview by Dr. med Dirk Einecke)].
Einecke D
MMW Fortschr Med; 2012 Jun; 154(12):28. PubMed ID: 22880293
[No Abstract] [Full Text] [Related]
17. An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study.
Blackberry ID; Furler JS; Ginnivan LE; Manski-Nankervis JA; Jenkins A; Cohen N; Best JD; Young D; Liew D; Ward G; O'Neal DN
Diabetes Res Clin Pract; 2014 Nov; 106(2):247-55. PubMed ID: 25271117
[TBL] [Abstract][Full Text] [Related]
18. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.
Bergenstal RM; Rosenstock J; Bastyr EJ; Prince MJ; Qu Y; Jacober SJ
Diabetes Care; 2014; 37(3):659-65. PubMed ID: 24198302
[TBL] [Abstract][Full Text] [Related]
19. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
20. [Intensive insulin therapy in type 2 diabetes mellitus].
Jermendy G
Orv Hetil; 2012 Sep; 153(38):1487-93. PubMed ID: 22985663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
